Cancer News and Research

Latest Cancer News and Research

Adding a dip can induce bitter sensitive children to eat more vegetables

There's an existential crisis that often happens at dinner tables across the country: why won't kids eat their vegetables? Research has found that one reason could be a sensitivity to bitterness, fairly common among children - about 70 percent have it.

2 Dec 2011

Researchers identify cancer cell mitochondria as 'Achilles' heel' of tumor growth

Researchers at the Kimmel Cancer Center at Jefferson have identified cancer cell mitochondria as the unsuspecting powerhouse and "Achilles' heel" of tumor growth, opening up the door for new therapeutic targets in breast cancer and other tumor types.

2 Dec 2011

Novelos prices underwritten public offering of $5,904,000 of common stock

Novelos Therapeutics, Inc., a pharmaceutical company developing novel drugs for treatment and diagnosis of cancer, today announced the pricing of an underwritten public offering of 9,840,000 units at $0.60 per unit for gross proceeds of $5,904,000.

2 Dec 2011

Two studies uncover limitations in screening for hepatocellular carcinoma

Two studies available in the December issue of Hepatology, a journal of the American Association for the Study of Liver Diseases, have uncovered limitations in screening for primary liver cancer, also known as hepatocellular carcinoma.

2 Dec 2011

Radioimmunotherapy shows promise against fungal diseases

Invasive fungal infections (IFI) are a major threat to individuals with cancer, transplants, HIV, and other conditions that weaken their immune system. New research has shown that radioimmunotherapy (RIT) could be a promising avenue for development of new types of treatment of fungal diseases, according to a paper published by scientists of the Joint Research Centre (JRC) in collaboration with other researchers.

2 Dec 2011

Idera receives FDA notification to proceed with IMO-3100 Phase 2 clinical trial for psoriasis

Idera Pharmaceuticals, Inc. today announced the receipt of verbal notification from the Food and Drug Administration that the company may proceed with a Phase 2 clinical trial of IMO-3100 in patients with psoriasis based on a trial protocol submitted by the company in October 2011.

2 Dec 2011

AVEO, Boehringer Ingelheim enter development and manufacturing agreement for ficlatuzumab

AVEO Pharmaceuticals, Inc. and Boehringer Ingelheim today announced that they have entered into an agreement for large-scale process development and clinical manufacturing of ficlatuzumab, AVEO's novel HGF inhibitory antibody that is currently in Phase 2 clinical development in patients with non-small cell lung cancer.

2 Dec 2011

EGCG may prevent HCV reinfection after liver transplantation

German researchers have determined that epigallocatechin-3-gallate (EGCG)—a flavonoid found in green tea—inhibits the hepatitis C virus (HCV) from entering liver cells.

1 Dec 2011

Body's surveillance for cancer causing damage and response to allergies share common pathway

CANCER RESEARCH UK scientists have found that the body's surveillance for cancer causing damage and its response to allergies share a common pathway, according to research published in Science on Thursday.

1 Dec 2011

Celldex launches rindopepimut Phase 3 trial in EGFRvIII-positive glioblastoma

Celldex Therapeutics, Inc. today announced that it has launched a pivotal, randomized, double-blind, controlled Phase 3 trial of rindopepimut in patients with surgically resected epidermal growth factor variant III (EGFRvIII)-positive glioblastoma, the "ACT IV Study."

1 Dec 2011

New discovery of adult stem cells gives fresh possibilities for heart regeneration

Sydney researchers have discovered a new population of adult stem cells in the heart, which could augment the development of new regeneration and repair therapies for people who have suffered heart attack or heart failure, the leading cause of death in Australia.

1 Dec 2011

Study presents high-resolution genome-wide p53-binding map for normal human cells

Scientists investigating the interactions, or binding patterns, of a major tumor-suppressor protein known as p53 with the entire genome in normal human cells have turned up key differences from those observed in cancer cells. The distinct binding patterns reflect differences in the chromatin (the way DNA is packed with proteins), which may be important for understanding the function of the tumor suppressor protein in cancer cells.

1 Dec 2011

Study reveals no clear advantage of one implant type over another

More than 270,000 Americans get hip replacement surgeries every year -- a number that is projected to double in the next decade as the population ages. With various options for implants, including metal-on-polyethylene, metal-on-metal and ceramic-on-ceramic, there have been questions about which kind works best.

1 Dec 2011

Compugen's Antibody Target Discovery Platform presented at 7th Annual European Antibody Congress

Speaking today at the plenary session of the 7th Annual European Antibody Congress in Geneva, Dr. Anat Cohen-Dayag, President and CEO of Compugen Ltd., presented Compugen's Antibody Target Discovery Platform, one of the Company's predictive discovery platforms for novel therapeutic targets.

1 Dec 2011

Cancer researchers create catalog of possible targets for new treatments

As cancer researchers continue to identify genetic mutations driving different cancer subtypes, they are also creating a catalog of possible targets for new treatments.

1 Dec 2011

Immune system stimulant used as suppressor to treat chronic graft-versus-host disease

In a study that seems to pivot on a paradox, scientists at Dana-Farber Cancer Institute have used an immune system stimulant as an immune system suppressor to treat a common, often debilitating side effect of donor stem cell transplantation in cancer patients. The effect, in some cases, was profound.

1 Dec 2011

First neurovascular unit opens at Krembil Neuroscience Centre

The first neurovascular unit (NVU) in Canada opened today at the Krembil Neuroscience Centre, Toronto Western Hospital, which is part of the University Health Network.

1 Dec 2011

Onconova uses BioClinica EDC, data management services to support clinical trials

BioClinica, Inc., a global provider of clinical trial management solutions, today announced that Onconova Therapeutics, Inc. has extended agreements using BioClinica Express electronic data capture (EDC) and data management services to support their clinical trials world-wide.

From Clario 1 Dec 2011

arGEN-X closes EUR 27.5 million Series B fundraising round

arGEN-X, a biopharmaceutical company focused on the discovery and development of human monoclonal antibodies from its proprietary SIMPLE Antibody platform, announced today the closing of a EUR 27.5 million (USD 37 million) Series B fundraising round, which was oversubscribed.

1 Dec 2011

Santaris Pharma wins two LNA patent re-examination cases in the U.S.

Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that it has won two significant patent re-examination cases brought by Isis Pharmaceuticals.

1 Dec 2011

Cancer News and Research

Latest Cancer News and Research

Adding a dip can induce bitter sensitive children to eat more vegetables

Researchers identify cancer cell mitochondria as 'Achilles' heel' of tumor growth

Novelos prices underwritten public offering of $5,904,000 of common stock

Two studies uncover limitations in screening for hepatocellular carcinoma

Radioimmunotherapy shows promise against fungal diseases

Idera receives FDA notification to proceed with IMO-3100 Phase 2 clinical trial for psoriasis

AVEO, Boehringer Ingelheim enter development and manufacturing agreement for ficlatuzumab

EGCG may prevent HCV reinfection after liver transplantation

Body's surveillance for cancer causing damage and response to allergies share common pathway

Celldex launches rindopepimut Phase 3 trial in EGFRvIII-positive glioblastoma

New discovery of adult stem cells gives fresh possibilities for heart regeneration

Study presents high-resolution genome-wide p53-binding map for normal human cells

Study reveals no clear advantage of one implant type over another

Compugen's Antibody Target Discovery Platform presented at 7th Annual European Antibody Congress

Cancer researchers create catalog of possible targets for new treatments

Immune system stimulant used as suppressor to treat chronic graft-versus-host disease

First neurovascular unit opens at Krembil Neuroscience Centre

Onconova uses BioClinica EDC, data management services to support clinical trials

arGEN-X closes EUR 27.5 million Series B fundraising round

Santaris Pharma wins two LNA patent re-examination cases in the U.S.

Understanding the DNA Damage Response in Innate Immunity eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Cancer News and Research

Latest Cancer News and Research

Understanding the DNA Damage Response in Innate Immunity eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Newsletters you may be interested in